Novo Nordisk (NVO: Quote) pronounced that a US Food and Drug Administration has supposed for examination a Class II Resubmissions for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart).
To safety a firmness of a ongoing DEVOTE trial, usually a tiny group within Novo Nordisk has entrance to a data. This group has prepared a halt research for a Class II resubmission and will correlate with a FDA during a review, on matters associated to a halt analysis.
As formerly indicated, a outcome of an halt research carries a aloft turn of doubt than a final investigate formula as this rough guess is built on a almost reduce series of observations. Accordingly, a relations risk guess subsequent from a halt research is so usually an denote of a final hearing results.
Novo Nordisk government does not have entrance to a formula of a halt analysis. The hearing is approaching to be finished in a second half of 2016.
by RTT Staff Writer
For comments and feedback: [email protected]